Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
MEchanical sTABility Of phosphoLIpids bilayerS in the presence of Microplastics (METABOLISM)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Spain,United States
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-06-01
End date: 2026-05-31
Duration (months): 36.0
Total project cost (EUR): 261380.64
EU funding (EUR): 261380.64
Participants: 2
Project status: TERMINATED

In recent years, the number of microplastics (plastic particles smaller than 5 mm) in the environment has exploded and is expected to continue to increase in the coming years. They are now found in the air we breathe, in drinkable water, in food and even in human blood or organs. Unfortunately, this pollution issue is accentuated by the environmental contamination with perfluoroalkyl and polyfluoroalkyl compounds (PFAS), known as "forever chemicals" and linked to cancer problems. These chemicals are also found everywhere, up to the human body and tend to adsorb on plastics. However, the understanding of the interaction of PFAS or microplastics with complex shapes, sizes and chemical compositions on living systems is missing. METABOLISM seeks therefore at adapting physicochemical and biophysical techniques and models to understand the adsorption/attachment of these systems, the stretching dynamics and the unzipping mechanism of lipid bilayers, mimicking cell membranes in the presence of contaminants. The project aims at developing an integrated platform to simultaneously image and measure the stress distribution within the bilayers and the adhesion forces at play, in order to quantify the dysfunction of the cell machinery. The stability of lung cells will also be probed to have new insight into the damaging induced by pollution on relevant living systems. Gaining understanding about this problematic will provide important new knowledge on the impact of contaminants on health and highlight the need to improve remediation strategies.

Keywords: interfacial tension,lipids,pfas,microplastics,adsorption dynamic,membrane
Piezo-driven theramesh: A revolutionary multifaceted actuator to repair the injured spinal cord (Piezo4Spine)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain,Italy,Portugal,Belgium,Germany,Austria
Call: EIC Pathfinder Open 2022 (HORIZON-EIC-2022-PATHFINDEROPEN-01, 2022)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 3537121.25
EU funding (EUR): 3537120.25
Participants: 7
Project status: SIGNED

Piezo4Spine aims to develop a novel multifactorial therapy for spinal cord injury (SCI) conceived as a disruptive platform enabling unprecedented multiscale actuation to drive functional neural repair by more accurately tackling SCI complexity. It originally relies on the pivotal role that mechanotransduction plays in the physiology and physiopathology of tissue and organ functions, never explored before for SCI. We will develop a 3D bioprinted mesh containing nanocarriers with therapeutic agents acting at two pivotal aspects of neural repair: mechanotransduction and inhibitory scarring using gene therapy strategies. Bioactive nanocarriers will base on cutting-edge nanoparticles whose release will be electrically triggered on-demand via wireless powering. Such 3D-theramesh offers a novel and exceptionally robust biomaterial for delivering agents at the lesion, controlling time and dose. Current advances on SCI therapies focus on rehabilitation, cell transplantation, drugs, biomaterials, and/or electrical stimulation. Although leading to partial sensory/motor recovery, chronic functional deficits limit daily living activities and shorten live expectancy in SCI patients, as they fail to promote successful axon regeneration at the lesion and awake lost functions. By a multidisciplinary consortium combining scientific, technological, clinical and industrial partners enriched by their interdisciplinarity, we envision to overcome limitations of current technologies by tackling multiple cellular targets involved in neural regeneration after SCI with a balanced combination of therapeutic interventions able to optimally promote functional recovery. These radical science-to-technology breakthroughs could enable, if successful, novel technologies and therapies for SCI and many other neural and non-neural pathologies in which some, but not necessarily all, of these targets are involved. Gender dimension will be implemented by ensuring that findings apply to society as a whole.

Keywords: atomic force microscopy,biomaterial,electrophysiology,fibroblast,hydrogel,motor training,nanoparticles,organic electronics,piezo mechanorreceptor,preclinical studies,rna,spinal cord injury
Enhancing endogenous regenerative response in mammals by redeploying Cranial Neural Crest Cells pluripotency developmental programs and positional identity remodeling (REGENECREST)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Cell Biology, Development, Stem Cells and R egeneration
Panel description: For all organisms : Structure and function of the cell, cell -cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: France
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2023-01-01
End date: 2027-12-31
Duration (months): 60.0
Total project cost (EUR): 1497500.0
EU funding (EUR): 1497500.0
Participants: 1
Project status: SIGNED

Cell differentiation progresses via a continuous lineage restriction process where cell potential is reduced as the embryo develops. Pluripotent embryonic cells can beget all somatic cell types, but this capacity is rapidly restricted during the formation of the three germ layers, each giving rise to distinct cell types. Uniquely among vertebrates, a stem cell-like population arising in the embryo rostral part ? called cranial neural crest cells (CNCC) ? challenges this paradigm. CNCC not only give rise to ectoderm derivatives, such as neurons and glia, but also to cell types canonically associated with the mesoderm such as bone and cartilage of the face. During my postdoctoral training I demonstrated that murine CNCC naturally reverse cell differentiation to return into a pluripotent state during development. In addition, I showed pre-migratory CNCC carry positional information reflective of their spatial origin in the neuroepithelium. However, this identity is subsequently erased with migratory CNCC forming a transcriptionally homogenous population, which later re-diversifies as CNCC undergo commitment events. In my research proposal, using single-cell transcriptomics and genomics assays I seek to uncover and characterize gene regulatory networks and chromatin rearrangements regulating the reemergence of pluripotency programs within CNCC and the underlying reprograming of cellular identity. CNCC represent a unique model to study the molecular mechanisms governing cell-intrinsic behavior but also the role of the niche, which may influence the sequence of events by cell-cell interactions during craniofacial ontogeny. The interdisciplinary scope of experimental strategies included in this proposal will help understand how these fundamental processes are regulated and might result in novel strategies to stimulate craniofacial tissue repair, as cell dedifferentiation and reconfiguration of positional identity are two essential milestones for endogenous regeneration.

Keywords: pluripotency,cell plasticity
Towards unravelling self-assembly/disassembly mechanisms of photo-switchable supramolecular gels by super-resolution microscopy and their use for drug crystallization (LIGHTSUPGEL)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-10-01
End date: 2025-09-30
Duration (months): 24.0
Total project cost (EUR): 181152.96
EU funding (EUR): 181152.96
Participants: 1
Project status: SIGNED

The overarching scientific goal of the LIGHTSUPGEL study is to design and synthetize novel reversible photo-switchable azobenzene and bis(urea)-based supramolecular gels, and to develop a super-resolution microscopy-based methodology to visualize the self-assembly and disassembly process in real-time with the aim of unravelling their underlying mechanisms. The cutting-edge combination of super-resolution STED and FLIM microscopies, together with environment-sensitive fluorescent probes, will be employed to spatially controlled photo-switch the gelation and de-gelation, and for first time, simultaneously monitor the process with nanoscopic resolution. Furthermore, the application of this new knowledge and novel photo-switchable gels in gel-mediated drug crystallization, will be explored. The possibility of light-triggered drug crystal harvesting photo-switchable gels offers, will be the first ever described non-invasive and reversible method to harvest crystals from gels. This new technology will mean a huge advance in the field of gel-phase drug crystallization, bringing it closer to its industrialization. By completing this ambitious multidisciplinary work, the applicant will be in an excellent position to create cross-disciplinary collaborations with research groups and industry across Europe and to becoming an independent researcher himself.

Keywords: supramolecular gels super resolution microscopy photo switchable gels sted flim drug crystallization
Develop tools that use genetic data to better classify complex human diseases (ClassifyDiseases)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Integrative B iology : from Genes and Genomes to S ystems
Panel description: For all organis ms: Genetics, epigenetics, genomics  and other ‘omics studies , bioinformatics, systems biology , genetic diseases , gene editing, innovative methods and modelling,  ‘omics for personalised  medicine
Countries involved: Denmark
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2023-08-01
End date: 2028-07-31
Duration (months): 60.0
Total project cost (EUR): 1975333.0
EU funding (EUR): 1975333.0
Participants: 1
Project status: SIGNED

Many common diseases are highly heterogeneous, meaning that two individuals can be diagnosed with the same disease but have very different progressions or respond very differently to the same medication. These heterogeneous diseases affect a sizeable proportion of the population. For example, approximately one in four people will develop a heterogeneous brain disorder (e.g., a neurological condition such as epilepsy or Parkinson’s Disease, or a psychiatric condition such as depression or schizophrenia) To effectively treat a patient with a heterogeneous disease, it is necessary to quickly and accurately identify their subtype. At present, patient subtypes are decided using only clinical observations, and the process is highly suboptimal. For example, the available subtypes are often incomplete or poorly-defined, meaning that many patients are wrongly classified or can not be classified at all. Previous research indicates that for many heterogeneous diseases, the classification of patients can be improved by incorporating genetic information. However, for this to become a reality, requires statistical tools that do not yet exist. My project will develop novel statistical tools for classifying heterogeneous diseases based on genetic information. My project will prioritize classification of two heterogeneous diseases: epilepsy and schizophrenia. However, I will ensure that my new tools are general, freely available and easy-to-use, so that other groups can construct classification models for many other diseases. Overall, my project has the potential to revolutionize how patients with heterogeneous diseases are treated, and to facilitate more widespread use of precision medicine.

Keywords: statistical genetics,gwas,complex diseases,personalized medicine
VULCAN: matter, powered from within (VULCAN)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Condensed Matter Physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Austria
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2023-09-01
End date: 2028-08-31
Duration (months): 60.0
Total project cost (EUR): 1965025.0
EU funding (EUR): 1965025.0
Participants: 1
Project status: SIGNED

Vulcan, the Roman god of blacksmithing, was revered in Europe since the Iron Age (1200-500 BC) for a powerful skill: controlling the macroscopic properties of metals (strength, ductility, toughness). To this day, thermal treatments such as annealing - cycles of high temperatures, alternated with slow cooling - remain an essential tool of material science. However, Vulcan’s traditional powers forge monolithic, static, and passive materials, and are laughably blunt instruments when compared to living materials, which dynamically reconfigure, repair, and rebuild themselves. Living systems provide proof-of-concepts for what can be achieved: assembling functional materials from elementary blocks that consume fuel. VULCAN: matter, powered from within, takes forging into the modern age, injecting energy directly through active agents present in the materials. It is experiment-driven and bottom-up, establishing novel experimental strategies to fabricate materials powered from within, with phases and structures that cannot be achieved via thermal treatments, and present non-conventional mechanical and rheological properties (self-healing, odd viscosities). The proposal notably aims to control the phase diagram of matter with spatiotemporal modulation of activity of the bath. We will devise an active bath of swimming bacteria to assemble macroscopic and 3D colloidal crystals and gels [Objective 1], with structures and at scales that cannot be achieved thermally. In parallel, we will devise exotic condensed phases of matter: 2D liquids of spinners and networks of active beams [Objective 2], made from large numbers of autonomous micromachines built from light-activated colloids. This is uncharted territory and an ambitious and high-risk goal, fueling VULCAN’s lasting impact – tearing down the boundary between Active Matter and Materials Science - and opening the path to a new class of materials, powered from within, with applications in (bio)engineering and photonics.

Keywords: active matter colloidal assembly
ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and non-union (ORTHO-ALLO-UNION). (ORTHO-ALLO-UNION)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
Action type: Research and Innovation actions
Countries involved: Spain,Italy,France,Germany,Portugal
Call: Clinical trials of combined Advanced Therapy Medicinal Products (ATMPs) (HORIZON-HLTH-2023-TOOL-05, 2023)
Start date: 2023-12-01
End date: 2028-11-30
Duration (months): 60.0
Total project cost (EUR): 10589006.25
EU funding (EUR): 10589006.25
Participants: 20
Project status: SIGNED

Bone fracture with delay or failure to heal is a condition with huge health impact. Although only a small proportion of long bone fractures evolve to non-union (5%), it is a first magnitude problem due to the number of new annual fractures and increasing incidence of complex fractures with high risk of non-consolidation, need for repeated procedures and years of patient disability. Bone autografts, autologous mesenchymal cells, or other complex interventions are used in this setting. The aim of this project is the development of a universal therapy for fractures with delay or failure to heal, aiming to a simple and wide access to allogenic cell therapy combined with biomaterial, in a broad number of patients. Rather than considering ATMP only as a last solution in established non-union fractures, this project advocates that the indication should be moved to an earlier timepoint. Patients will be treated with the combined ATMP as soon as the need for reoperation is identified due to delayed healing, with or without an added infectious component, to avoid long-term suffering for patients and their relatives, and prevent progression to more severe non-unions, with heavy personal, social and economic costs. This approach is aligned with the real needs of patients and better fits with the usual practice in the EU, where reoperations are performed at 6 months or before, in an attempt to accelerate bone healing and avoid complications. The project will establish a master cell bank for a wide allogenic production with donors selection criteria of bone formation potential. Necessary preclinical and clinical information to support the EU approval of a specific combined ATMP will be obtained. Open access to scientific and regulatory information will be available for other EU medical device companies and cell therapy producers, so in addition to direct clinical benefit to patients and healthcare providers, other developers of combined ATMP products will get benefit.

Keywords: allo bm msc,non union
Harness lncRNA targeting to treat colorectal cancer (LINCURE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Spain,Italy
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2025-POC, 2025)
Start date: 2026-03-01
End date: 2027-08-31
Duration (months): 18.0
Total project cost (EUR): 167142.86
EU funding (EUR): 150000.0
Participants: 2
Project status: SIGNED

Colorectal cancer (CRC) is the third leading cause of cancer-related death globally. Despite the therapeutic advances, innate and acquired resistance is still an adversity that needs to be overcome. Therefore, there is an urgent need to identify more targeted and specific therapeutic approaches in order to increase success of the treatment and reduce the medical and economic burden of therapeutic failures. Numerous studies have been conducted to target the replication stress response, a hallmark of cancer and drug resistance, in cancer therapy. However, hitting this essential pathway can trigger deleterious and non-specific cellular responses. Our research introduces a novel perspective to this problem by focusing on the RNA components of the replication stress pathway. lncRNAs are untranslated RNAs whose emerging role in regulating gene expression has changed the way we look at genes and their functions. lncRNAs play a regulatory role in mechanisms of acquired tumour drug resistance. Moreover, their rapid turnover, tissue and pathology specificity make them ideal targets for effective therapeutic avenues that don’t bare the same toxicity as conventional approaches. Our dedicated ERC research has unveiled a lncRNA with remarkable biological properties. CRC cells subjected to replicative stress are addicted to its expression, representing a highly promising therapeutic target. Building on these novel findings, we propose LINCURE, a new therapy based on the inhibition of this lncRNA. lncRNA inhibitors will be used alone or in combination with the conventional 5-FU therapy to reach therapeutic efficacy for drug resistant CRC. We will integrate our unique knowledge with recent advancements in the successful development of delivery methods for RNA-based therapies, which have generated a surge of optimism in the realm of RNA therapeutics. The objective is to start a promising pathway toward translating our findings into effective clinical therapies.
Engineering Phosphorescent and TADF small molecules for white Light-emitting Electrochemical Cells (PoTA-LEC)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-06-01
End date: 2024-05-31
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 1
Project status: CLOSED

Light-emitting electrochemical cells (LECs) are getting much attention as single-layered, cost-effective (air-stable electrodes, spray deposition, tolerance to 3D substrates), and moderate performing devices. To date, the best emitters are conjugated polymers (CP) or anionic transition metal complex (iTMC), however, they still encounter serious hitches with respect to self-stability and sustainability. Hence, the LEC community exercised to find new rainbow emitters. Among them, SMs are considered the next generation due to the recent major achievements in NIR and white LECs. To advance this emerging field, PoTA-LEC aims at developing a full-fledged phosphorescent and TADF SM (possibilities of harvesting both 25% of singlet excitons and 75% triplet excitons) design to achieve highly performing rainbow LECs. Based on the SM-LEC and organic light emitting diode (OLED) prior arts, this project will focus on two action lines i) ionic/neutral phosphorescent SMs with peripheral bulky groups and covalently linked host moieties to enhance PLQYs and device efficiency, and ii) ionic/neutral rainbow TADF emitters used as single emitters or hosts. Optimized monochromatic LECs will be targeted, and the best SMs will be used in white LECs.

Keywords: organic small molecules,photophysics and optical spectroscopy,dual emission,phosphorescence,thermally activated delayed fluorescence,electrochemistry,liquid electrochemical cell,and fabrication